At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 51 enrolled
Drug / intervention
Uproleselan +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
In Brief
A Phase 2 clinical trial evaluating Uproleselan, Placebo, and 1 other intervention for Multiple Myeloma. Completed, enrolled 51 participants across 1 site.
Detailed Summary
The investigators hypothesize that prophylactic E-selectin inhibition via administration of uproleselan during melphalan conditioning will reduce the gastrointestinal (GI) toxicity in multiple myeloma (MM) patients undergoing auto-transplant, as assessed via diarrhea severity scoring per CTCAE v5.0, while potentially increasing chemosensitivity of malignant MM cells to high-dose melphalan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartMay 2021
Primary CompletionNov 2022
TodayJul 2026
First PostedDec 23, 2020
Enrollment StartMay 5, 2021
Primary CompletionNov 11, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.5 years ago
Interventions
Uproleselandrug
Provided by study
Placebodrug
Provided by study
Melphalandrug
-Standard of care